Skip to main content
. 2017 Apr 20;17:58. doi: 10.1186/s12876-017-0611-z

Table 2.

Indications of sirolimus therapy

Variable N (%)
Renal dysfunctiona 318 (55.2)
HCC
 Prophylaxis 93 (16.1)
 Recurrence 21 (3.6)
Non-hepatic tumors 18 (3.1)
Biopsy proved acute/chronic rejection 84 (14.6)
Neurotoxicity 5 (0.9)
Other side effects from immunosuppressants 37 (6.4)

aDefined by physician’s criteria or eGFR <60 mL/min/1.73 m2 without other reasons for SRL use